Helix Biopharma Corp banner

Helix Biopharma Corp
F:HBP

Watchlist Manager
Helix Biopharma Corp Logo
Helix Biopharma Corp
F:HBP
Watchlist
Price: 0.55 EUR 0.92% Market Closed
Market Cap: €77.6m

Wall St Price Targets

HBP Price Targets Summary
Helix Biopharma Corp

There are no price targets for HBP.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
Helix Biopharma Corp Competitors:
Price Targets
ZEAL
Zealand Pharma A/S
40% Upside
KRNY
Kearny Financial Corp
9% Upside
EBMT
Eagle Bancorp Montana Inc
11% Upside

Revenue
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for Helix Biopharma Corp

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is HBP's stock price target?
Not Available

HBP does not have any price targets made by Wall Street professionals.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett